AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ:AGMB

Biotechnology

Healthcare
$5.82 +2.48%

+$0.25 today

Market cap
$286.62M
Beta
2.62
P/E (TTM)
-7.1
EPS (TTM)
-$1.28
52W Low $8.75High $17.45

Volume 0.13M

Average 0.14M

Returns on capital

AgomAb Therapeutics N.V. American Depositary Shares management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

0.0%

avg 0.0%

ROIC

0.0%

avg 0.0%

ROA

0.0%

avg 0.0%

Analysis

ROE is currently the strongest return metric at 0.0% versus its period average of 0.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andrea Sáez Borderías

Chief Development Officer—44——

Paul Van Der Horst

Chief Business Officer—38——

Tim Knotnerus

CEO & Executive Director—43——

Paolo Michieli

Founder, Senior Advisor & Member of Scientific Advisory Board————

Pierre Kemula

Chief Financial Officer—52——

Philippe Wiesel

Chief Medical Officer—59——

Ellen Lefever

General Counsel—41——

Sofie Van Gijsel

Vice President of Investor Relations————

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

13

$503,470.00

Sells

0

$0.00

Net Transaction Value

+$503,470.00

Net buying

Most Active

Epstein David R

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Epstein David R

Direct

Buy$34.6K
Nov 5, 26

Epstein David R

Direct

Buy$34.9K
Nov 5, 26

Epstein David R

Direct

Buy$34.1K
Oct 21, 26

Epstein David R

Direct

Buy$44.5K
Oct 21, 26

Epstein David R

Direct

Buy$44.3K
Oct 8, 26

Epstein David R

Direct

Buy$44.5K
Oct 6, 26

Kemula Pierre Thadee Victor

Direct

Buy$17.1K
Oct 6, 26

Epstein David R

Direct

Buy$43.5K
Oct 6, 26

Kemula Pierre Thadee Victor

Direct

Buy$42.9K
Oct 6, 26

Kemula Pierre Thadee Victor

Direct

Buy$26K

1–10 of 13

Summary

Insiders reported 13 buys worth $503,470.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $503,470.00. Epstein David R was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does AgomAb Therapeutics N.V. American Depositary Shares compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AGMB's management, answered from reported figures.

Who manages AGMB?

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) lists 8 active executives. The top listed executive is Andrea Sáez Borderías, Chief Development Officer.

Are AGMB insiders buying or selling?

Recent insider activity shows net buying of $2.09M.